Larimar Therapeutics Inc LRMR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LRMR is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $6.46
- Day Range
- $6.32–6.50
- 52-Week Range
- $2.18–13.68
- Bid/Ask
- $6.01 / $6.99
- Market Cap
- $412.15 Mil
- Volume/Avg
- 222,439 / 686,384
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 42
- Website
- https://www.larimartx.com
Comparables
Valuation
Metric
|
LRMR
|
CELC
|
VRDN
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.47 | 3.15 | 2.99 |
Price/Sales | — | — | 1,857.18 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
LRMR
|
CELC
|
VRDN
|
---|---|---|---|
Quick Ratio | 9.13 | 12.78 | 17.93 |
Current Ratio | 9.49 | 13.43 | 18.26 |
Interest Coverage | — | −12.43 | −137.76 |
Quick Ratio
LRMR
CELC
VRDN
Profitability
Metric
|
LRMR
|
CELC
|
VRDN
|
---|---|---|---|
Return on Assets (Normalized) | −26.34% | −35.57% | −42.76% |
Return on Equity (Normalized) | −29.84% | −49.08% | −82.42% |
Return on Invested Capital (Normalized) | −28.31% | −39.21% | −50.70% |
Return on Assets
LRMR
CELC
VRDN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wkzlzgjfdt | Jvgn | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mwhpkqzm | Fcbbbcp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jmfblfp | Qkzdxb | $99.5 Bil | |
MRNA
| Moderna Inc | Tbgvfxrt | Thgp | $38.8 Bil | |
ARGX
| argenx SE ADR | Prgbrvy | Wldj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zvxjybrz | Lvb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dgrxxhv | Rbchlf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fdfdstvb | Krfqyq | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wrxnjrhdq | Hpwhlfk | $12.5 Bil | |
INCY
| Incyte Corp | Rvfpdzg | Zdzbgj | $11.6 Bil |